Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients
NCT ID: NCT00627731
Last Updated: 2011-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2007-06-30
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Inhaled Glucocorticosteroid Administration in Asthma Patients
NCT00559689
Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma
NCT01687296
Acute Montelukast in Asthma
NCT01011452
Oral Prednisolone Dosing in Children Hospitalized With Asthma
NCT00257933
Steroids In The Management Of Acute Asthma Exacerbations In Children, Which Form Is More Suitable?
NCT03204760
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
mPSL 240 mg per day for 5 days
methylprednisolone sodium succinate (mPSL)
mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
2
PSL 40mg per day for 10 days
prednisolone (PSL)
PSL 40 mg per day for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
methylprednisolone sodium succinate (mPSL)
mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
prednisolone (PSL)
PSL 40 mg per day for 10 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* With severe complications
* Received systemic glucocorticosteroid therapy in the previous 4 weeks
16 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hamamatsu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Naoki Inui
Department of Respiratory Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kingo Chida, MD,PhD
Role: STUDY_CHAIR
Hamamatsu University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hamamatsu University School of Medicine
Hamamatsu, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hamamatsu-1968
Identifier Type: -
Identifier Source: secondary_id
Hamamatsu-18-68
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.